Can-Fite BioPharma (CANF) 20-F2020 FY Annual report (foreign)

Filed: 25 Mar 21, 8:40am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: Acute, adipocyte, Akero, alive, alliance, ANOVA, antagonist, approva, ASC, Asher, AstraZeneca, ASU, Biden, bifurcation, BioNTech, biopsy, blocker, Bonferroni, broken, byAmgen, CAP, captured, CEE, CFB, closure, Codification, consequential, Daniel, Democratic, disappearance, dissipate, distinct, diverge, downsizing, drop, Dung, Eastern, ED, elastography, electoral, embedded, EP, EPS, Ewopharma, exit, FASB, feature, GAAP, globe, hardship, Harrison, Hepatology, HK, Holy, IDMC, immunotherapy, inhibitory, Intracoastal, IP, IRBl, Johnson, Joseph, jurisdiction, Kopin, longevity, matching, missed, Mitchell, Moderna, multiorgan, nanomolar, Nazareth, neutralized, nM, noninvasive, Novavax, OCA, Oxford, oxygen, Parameter, PCFB, Petach, Pinnacle, pneumonia, PPACA, Prof, PTO, pursuit, Radcliffe, radiographic, recived, Reconciliation, reconciling, recoup, Regeneron, regime, remdesivir, renegotiate, resource, resubmission, rich, SD, sector, Senate, shift, SNS, spectrum, SSC, stable, Stadler, Stephen, SUBSIDIARIY, susceptible, thirteen, threat, tied, tracing, undiscounted, unrecognized, unsatisfactory, vaccine, Veklury, Viking, Visiting, Vriew, workplace, younger

Removed: abnormal, Allergan, Amending, andin, anemia, anin, ascertained, assaysin, assumption, autoimmunity, baricitninib, bone, cartilage, chemotherapeutic, choose, chronicity, commitment, comparability, compelling, computation, computed, consistently, corroborated, cured, cushioning, Dash, debtor, Derecognition, derecognized, DIC, diffuse, discovering, disposed, distinguish, dividing, earliest, embodying, estimating, evaporation, extinguished, eyefite, facilitate, fight, film, finalized, flexible, fluid, frame, fusion, ganglion, goodwill, guaranteed, guaranteeing, hearing, includein, inin, intragroup, irritation, JAK, kinase, leflunomide, legally, lowest, lymphoma, Meitav, membrane, migrate, minimizing, modifiable, mononuclear, neuropathy, nodular, ocular, optic, outflow, participant, pattern, peripheral, plaquenil, Plenum, postmenopausal, postponement, propose, prospectively, reading, relocation, researching, resultant, retina, retinal, rub, Sabby, Seikagaku, settle, sexual, spinoff, Steroidal, strategically, subPatent, sulfasalazine, swelling, symmetry, synovial, tear, terminating, tofacitinib, translating, Ultratrend, unadjusted, uniform, unrestricted, unused, verified, virtually, Visiongain, visual, Wainwright, warmth, wearing, Xeljanz

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

CANF similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 13.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT

Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Can-Fite BioPharma Ltd. (the “Company”) hereby certifies to such officer’s knowledge that:

(i) the accompanying Annual Report on Form 20-F of the Company for the year ended December 31, 2020 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: March 25, 2021

/s/ Motti Farbstein
Motti Farbstein
Chief Operating and Financial Officer

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference to any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.